Tourmaline Bio News

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients

GlobeNewswireMay 23 07:10 ET

Express News | Tourmaline Bio Inc: Topline Data Anticipated in First Half of 2025

ReutersMay 16 07:04 ET

Express News | Tourmaline Bio Initiates Clinical Development of Tour006 for Cardiovascular Diseases With First Patient Dosed in Phase 2 Tranquility Trial

ReutersMay 16 07:00 ET

Truist Financial Reaffirms Their Buy Rating on Tourmaline Bio (TRML)

TipRanksMay 14 10:05 ET

Express News | HC Wainwright & Co. Reiterates Buy on Tourmaline Bio, Maintains $48 Price Target

BenzingaMay 14 09:57 ET

Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)

TipRanksMay 14 09:50 ET

Tourmaline Bio | 10-Q: Quarterly report

SEC announcementMay 13 16:20 ET · Announcements

Express News | Tourmaline Bio Ended The First Quarter With $350.3M Of Cash, Cash Equivalents And Investments, Providing Cash Runway Into 2027

BenzingaMay 13 07:19 ET

Express News | Tourmaline Bio Q1 2024 GAAP EPS $(0.55) Beats $(0.66) Estimate

BenzingaMay 13 07:18 ET

Express News | Tourmaline Bio Inc Q1 Shr View $-0.67 -- Lseg Ibes Data

ReutersMay 13 07:17 ET

Express News | Tourmaline Bio Inc - Qtrly Shr Loss $0.55

ReutersMay 13 07:17 ET

Express News | Tourmaline Bio Inc - Ended the Quarter With $350.3 Million of Cash, Cash Equivalents and Investments, Providing Cash Runway Into 2027

ReutersMay 13 07:16 ET

Tourmaline Bio 1Q Loss/Shr 55c >TRML

Tourmaline Bio 1Q Loss/Shr 55c >TRML

Dow JonesMay 13 07:04 ET

Express News | Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

ReutersMay 13 07:00 ET

Press Release: Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights -- Initiated Phase 2 TRANQUILITY trial in April 2024 following U.S. FDA clearance of Investigational New Dru

Dow JonesMay 13 07:00 ET

Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler

Seeking AlphaApr 12 11:34 ET

Tourmaline Bio Price Target Maintained With a $74.00/Share by Truist Securities

Tourmaline Bio Price Target Maintained With a $74.00/Share by Truist Securities

Dow JonesMar 25 12:37 ET

Truist Financial Keeps Their Buy Rating on Tourmaline Bio (TRML)

TipRanksMar 25 08:25 ET

PHIO and MGRM Among Healthcare Movers

Seeking AlphaMar 21 10:12 ET

Dow Jumps 200 Points; US Weekly Jobless Claims Fall

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.52% to 39,718.37 while the NASDAQ ros

BenzingaMar 21 09:47 ET